Although most gastroenterologists feel that store-brand and branded treatments are equivalent, most continue to recommend branded products for gastroesophageal reflux disease and chronic constipation, according to two studies presented at the annual Digestive Disease Week, held from May 3 to 6 in Chicago.
Results from the PEARL-II study show treatment-experienced patients with hepatitis C genotype 1b achieved SVR rates of greater than 96% when treated with a combination of ABT 450 with ritonavir, co-formulated with ombitasvir and dasabuvir, without the need for ribavirin.
Patients with celiac disease treated with larazotide acetate experienced improvements in GI symptoms and non-GI symptoms such as headache and fatigue, as well as significant reductions in the number of symptomatic days.
For patients undergoing colonoscopy, L-menthol sprayed directly onto the colonic mucosa improves the adenoma detection rate, according to a study presented at the annual Digestive Disease Week, held from May 3 to 6 in Chicago.
A new regimen shows promise for hepatitis C virus (HCV) genotype 1 infection, and sofosbuvir and ribavirin are active in HCV genotypes 2 and 3 infection, according to two studies published online May 4 in the New England Journal of Medicine. This research was published to coincide with the annual Digestive Disease Week, held from May 3 to 6 in Chicago.